IL89352A - Milk anti-hypertensive factor, method for the production thereof and pharmaceutical compositions containing the same - Google Patents
Milk anti-hypertensive factor, method for the production thereof and pharmaceutical compositions containing the sameInfo
- Publication number
- IL89352A IL89352A IL8935289A IL8935289A IL89352A IL 89352 A IL89352 A IL 89352A IL 8935289 A IL8935289 A IL 8935289A IL 8935289 A IL8935289 A IL 8935289A IL 89352 A IL89352 A IL 89352A
- Authority
- IL
- Israel
- Prior art keywords
- milk
- factor
- hypertensive
- molecular weight
- antihypertensive
- Prior art date
Links
- 235000013336 milk Nutrition 0.000 title claims abstract description 120
- 210000004080 milk Anatomy 0.000 title claims abstract description 120
- 239000008267 milk Substances 0.000 title claims abstract description 119
- 230000003276 anti-hypertensive effect Effects 0.000 title claims abstract description 57
- 238000000034 method Methods 0.000 title claims description 42
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 4
- 238000004519 manufacturing process Methods 0.000 title description 7
- 206010020772 Hypertension Diseases 0.000 claims abstract description 28
- 241001465754 Metazoa Species 0.000 claims description 30
- 239000000203 mixture Substances 0.000 claims description 13
- 230000008569 process Effects 0.000 claims description 12
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 10
- WFIYPADYPQQLNN-UHFFFAOYSA-N 2-[2-(4-bromopyrazol-1-yl)ethyl]isoindole-1,3-dione Chemical compound C1=C(Br)C=NN1CCN1C(=O)C2=CC=CC=C2C1=O WFIYPADYPQQLNN-UHFFFAOYSA-N 0.000 claims description 8
- 238000001556 precipitation Methods 0.000 claims description 7
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 6
- 239000000725 suspension Substances 0.000 claims description 6
- 239000002808 molecular sieve Substances 0.000 claims description 4
- URGAHOPLAPQHLN-UHFFFAOYSA-N sodium aluminosilicate Chemical compound [Na+].[Al+3].[O-][Si]([O-])=O.[O-][Si]([O-])=O URGAHOPLAPQHLN-UHFFFAOYSA-N 0.000 claims description 4
- 238000004255 ion exchange chromatography Methods 0.000 claims description 3
- 229920002521 macromolecule Polymers 0.000 claims description 3
- 239000012153 distilled water Substances 0.000 claims 4
- 238000004587 chromatography analysis Methods 0.000 claims 2
- 238000007918 intramuscular administration Methods 0.000 claims 1
- 238000007912 intraperitoneal administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 241000124008 Mammalia Species 0.000 abstract description 2
- 239000000427 antigen Substances 0.000 description 52
- 108091007433 antigens Proteins 0.000 description 52
- 102000036639 antigens Human genes 0.000 description 52
- 241000283690 Bos taurus Species 0.000 description 34
- 230000000521 hyperimmunizing effect Effects 0.000 description 29
- 230000000694 effects Effects 0.000 description 23
- 230000001580 bacterial effect Effects 0.000 description 22
- 241000282817 Bovidae Species 0.000 description 18
- 238000012360 testing method Methods 0.000 description 13
- 229960005486 vaccine Drugs 0.000 description 12
- 241000894006 Bacteria Species 0.000 description 11
- 238000011282 treatment Methods 0.000 description 11
- 238000002649 immunization Methods 0.000 description 10
- 230000003053 immunization Effects 0.000 description 10
- 239000000047 product Substances 0.000 description 9
- 235000020183 skimmed milk Nutrition 0.000 description 9
- 230000001631 hypertensive effect Effects 0.000 description 8
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 7
- 239000002220 antihypertensive agent Substances 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 230000035488 systolic blood pressure Effects 0.000 description 7
- 229940127088 antihypertensive drug Drugs 0.000 description 6
- 230000004872 arterial blood pressure Effects 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 239000011859 microparticle Substances 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 238000000746 purification Methods 0.000 description 6
- 208000007530 Essential hypertension Diseases 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- 239000005862 Whey Substances 0.000 description 5
- 210000004027 cell Anatomy 0.000 description 5
- 239000012154 double-distilled water Substances 0.000 description 5
- 230000003287 optical effect Effects 0.000 description 5
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 206010070834 Sensitisation Diseases 0.000 description 4
- 102000007544 Whey Proteins Human genes 0.000 description 4
- 108010046377 Whey Proteins Proteins 0.000 description 4
- 230000002411 adverse Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 230000036772 blood pressure Effects 0.000 description 4
- 230000008859 change Effects 0.000 description 4
- 239000003814 drug Substances 0.000 description 4
- 239000000706 filtrate Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000002955 isolation Methods 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 230000035945 sensitivity Effects 0.000 description 4
- 230000008313 sensitization Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 229920002271 DEAE-Sepharose Polymers 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 239000002934 diuretic Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 230000002526 effect on cardiovascular system Effects 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 235000012907 honey Nutrition 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 239000011159 matrix material Substances 0.000 description 3
- 238000009928 pasteurization Methods 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 210000002966 serum Anatomy 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 230000002889 sympathetic effect Effects 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 229940124549 vasodilator Drugs 0.000 description 3
- 239000003071 vasodilator agent Substances 0.000 description 3
- 239000003981 vehicle Substances 0.000 description 3
- 102000015427 Angiotensins Human genes 0.000 description 2
- 108010064733 Angiotensins Proteins 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 208000019693 Lung disease Diseases 0.000 description 2
- 206010028813 Nausea Diseases 0.000 description 2
- 201000004239 Secondary hypertension Diseases 0.000 description 2
- 241000194019 Streptococcus mutans Species 0.000 description 2
- 206010047700 Vomiting Diseases 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 229960001212 bacterial vaccine Drugs 0.000 description 2
- 239000002876 beta blocker Substances 0.000 description 2
- 229940097320 beta blocking agent Drugs 0.000 description 2
- 230000004071 biological effect Effects 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 235000019504 cigarettes Nutrition 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 229920001577 copolymer Polymers 0.000 description 2
- 239000006071 cream Substances 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 229940030606 diuretics Drugs 0.000 description 2
- 238000002651 drug therapy Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 238000002523 gelfiltration Methods 0.000 description 2
- 239000001963 growth medium Substances 0.000 description 2
- 210000002216 heart Anatomy 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001965 increasing effect Effects 0.000 description 2
- 238000010255 intramuscular injection Methods 0.000 description 2
- 239000007927 intramuscular injection Substances 0.000 description 2
- 238000005342 ion exchange Methods 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 229940031348 multivalent vaccine Drugs 0.000 description 2
- 230000008693 nausea Effects 0.000 description 2
- 239000008188 pellet Substances 0.000 description 2
- 230000000737 periodic effect Effects 0.000 description 2
- 238000005191 phase separation Methods 0.000 description 2
- 229920000642 polymer Polymers 0.000 description 2
- 230000002685 pulmonary effect Effects 0.000 description 2
- 235000015598 salt intake Nutrition 0.000 description 2
- 230000000391 smoking effect Effects 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 208000019553 vascular disease Diseases 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- 230000008673 vomiting Effects 0.000 description 2
- AGIJRRREJXSQJR-UHFFFAOYSA-N 2h-thiazine Chemical compound N1SC=CC=C1 AGIJRRREJXSQJR-UHFFFAOYSA-N 0.000 description 1
- ABXZHBOLRVUXPK-UHFFFAOYSA-N 3-aminopropyl carbamimidothioate Chemical compound NCCCSC(N)=N ABXZHBOLRVUXPK-UHFFFAOYSA-N 0.000 description 1
- 208000020154 Acnes Diseases 0.000 description 1
- 241000186046 Actinomyces Species 0.000 description 1
- 208000010470 Ageusia Diseases 0.000 description 1
- 108010068307 Alpha-Globulins Proteins 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 206010002660 Anoxia Diseases 0.000 description 1
- 241000976983 Anoxia Species 0.000 description 1
- 206010060965 Arterial stenosis Diseases 0.000 description 1
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 1
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 1
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
- 108010087504 Beta-Globulins Proteins 0.000 description 1
- 241000283725 Bos Species 0.000 description 1
- 238000009631 Broth culture Methods 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 206010071200 Carbohydrate intolerance Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 206010007559 Cardiac failure congestive Diseases 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 208000017701 Endocrine disease Diseases 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 208000010201 Exanthema Diseases 0.000 description 1
- 241000606790 Haemophilus Species 0.000 description 1
- 206010019233 Headaches Diseases 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- 241000701149 Human adenovirus 1 Species 0.000 description 1
- 241001135574 Human adenovirus 12 Species 0.000 description 1
- 241000701122 Human adenovirus 18 Species 0.000 description 1
- 241001135569 Human adenovirus 5 Species 0.000 description 1
- 241000193096 Human adenovirus B3 Species 0.000 description 1
- 241001428586 Human adenovirus D8 Species 0.000 description 1
- 208000035150 Hypercholesterolemia Diseases 0.000 description 1
- 208000019025 Hypokalemia Diseases 0.000 description 1
- 206010021131 Hypouricaemia Diseases 0.000 description 1
- 206010021143 Hypoxia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 241000588915 Klebsiella aerogenes Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 206010050551 Lupus-like syndrome Diseases 0.000 description 1
- 102000014171 Milk Proteins Human genes 0.000 description 1
- 108010011756 Milk Proteins Proteins 0.000 description 1
- 241000551546 Minerva Species 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 206010033307 Overweight Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 241001648298 Propionivibrio Species 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000589517 Pseudomonas aeruginosa Species 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000001647 Renal Insufficiency Diseases 0.000 description 1
- 241001354013 Salmonella enterica subsp. enterica serovar Enteritidis Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- 108010045362 Serum Globulins Proteins 0.000 description 1
- 102000005686 Serum Globulins Human genes 0.000 description 1
- 241000607764 Shigella dysenteriae Species 0.000 description 1
- 241000193998 Streptococcus pneumoniae Species 0.000 description 1
- 208000001871 Tachycardia Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000000464 adrenergic agent Substances 0.000 description 1
- 239000000674 adrenergic antagonist Substances 0.000 description 1
- 235000019666 ageusia Nutrition 0.000 description 1
- 230000004523 agglutinating effect Effects 0.000 description 1
- 229960002478 aldosterone Drugs 0.000 description 1
- 230000001668 ameliorated effect Effects 0.000 description 1
- 238000005571 anion exchange chromatography Methods 0.000 description 1
- 230000007953 anoxia Effects 0.000 description 1
- 230000001466 anti-adreneric effect Effects 0.000 description 1
- 230000002456 anti-arthritic effect Effects 0.000 description 1
- 229940030600 antihypertensive agent Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 108091008698 baroreceptors Proteins 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000004531 blood pressure lowering effect Effects 0.000 description 1
- 238000009530 blood pressure measurement Methods 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 231100000315 carcinogenic Toxicity 0.000 description 1
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 235000020247 cow milk Nutrition 0.000 description 1
- 235000014048 cultured milk product Nutrition 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 208000002925 dental caries Diseases 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000011026 diafiltration Methods 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004882 diastolic arterial blood pressure Effects 0.000 description 1
- 230000035487 diastolic blood pressure Effects 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 208000002173 dizziness Diseases 0.000 description 1
- 230000035622 drinking Effects 0.000 description 1
- 230000009982 effect on human Effects 0.000 description 1
- 230000003028 elevating effect Effects 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 208000030172 endocrine system disease Diseases 0.000 description 1
- 201000005884 exanthem Diseases 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- -1 fatty acid esters Chemical class 0.000 description 1
- 239000012467 final product Substances 0.000 description 1
- 230000004907 flux Effects 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 108010074605 gamma-Globulins Proteins 0.000 description 1
- 238000001641 gel filtration chromatography Methods 0.000 description 1
- 238000007429 general method Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 231100000869 headache Toxicity 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 244000144980 herd Species 0.000 description 1
- 239000013628 high molecular weight specie Substances 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 239000005555 hypertensive agent Substances 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- 230000008086 immune related sensitivity Effects 0.000 description 1
- 230000006058 immune tolerance Effects 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000010406 interfacial reaction Methods 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 201000006370 kidney failure Diseases 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 201000002364 leukopenia Diseases 0.000 description 1
- 231100001022 leukopenia Toxicity 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 239000004005 microsphere Substances 0.000 description 1
- 235000021239 milk protein Nutrition 0.000 description 1
- 231100000324 minimal toxicity Toxicity 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000008035 nerve activity Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 238000010979 pH adjustment Methods 0.000 description 1
- 210000001002 parasympathetic nervous system Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 208000028591 pheochromocytoma Diseases 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 239000002574 poison Substances 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 208000024896 potassium deficiency disease Diseases 0.000 description 1
- 210000001774 pressoreceptor Anatomy 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 201000001474 proteinuria Diseases 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 206010037844 rash Diseases 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 239000006215 rectal suppository Substances 0.000 description 1
- 238000007670 refining Methods 0.000 description 1
- 230000011514 reflex Effects 0.000 description 1
- 102000037983 regulatory factors Human genes 0.000 description 1
- 108091008025 regulatory factors Proteins 0.000 description 1
- 229940108461 rennet Drugs 0.000 description 1
- 108010058314 rennet Proteins 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 229940007046 shigella dysenteriae Drugs 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000021262 sour milk Nutrition 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 239000012134 supernatant fraction Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 210000002820 sympathetic nervous system Anatomy 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 230000006794 tachycardia Effects 0.000 description 1
- 210000005182 tip of the tongue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23C—DAIRY PRODUCTS, e.g. MILK, BUTTER OR CHEESE; MILK OR CHEESE SUBSTITUTES; MAKING OR TREATMENT THEREOF
- A23C9/00—Milk preparations; Milk powder or milk powder preparations
- A23C9/20—Dietetic milk products not covered by groups A23C9/12 - A23C9/18
-
- A—HUMAN NECESSITIES
- A24—TOBACCO; CIGARS; CIGARETTES; SIMULATED SMOKING DEVICES; SMOKERS' REQUISITES
- A24B—MANUFACTURE OR PREPARATION OF TOBACCO FOR SMOKING OR CHEWING; TOBACCO; SNUFF
- A24B15/00—Chemical features or treatment of tobacco; Tobacco substitutes, e.g. in liquid form
- A24B15/18—Treatment of tobacco products or tobacco substitutes
- A24B15/28—Treatment of tobacco products or tobacco substitutes by chemical substances
- A24B15/30—Treatment of tobacco products or tobacco substitutes by chemical substances by organic substances
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
- C07K2317/11—Immunoglobulins specific features characterized by their source of isolation or production isolated from eggs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Toxicology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Heart & Thoracic Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Cardiology (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Dairy Products (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US07/161,039 US4879110A (en) | 1983-10-27 | 1988-02-26 | Antihypertensive hyperimmune milk, production, composition, and use |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL89352A0 IL89352A0 (en) | 1989-09-10 |
| IL89352A true IL89352A (en) | 1994-06-24 |
Family
ID=22579548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL8935289A IL89352A (en) | 1988-02-26 | 1989-02-21 | Milk anti-hypertensive factor, method for the production thereof and pharmaceutical compositions containing the same |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US4879110A (de) |
| EP (1) | EP0330521B1 (de) |
| JP (1) | JP2792973B2 (de) |
| AT (1) | ATE88349T1 (de) |
| AU (1) | AU621604B2 (de) |
| CA (1) | CA1339760C (de) |
| DE (1) | DE68906054T2 (de) |
| DK (1) | DK201590A (de) |
| ES (1) | ES2039847T3 (de) |
| IE (1) | IE63032B1 (de) |
| IL (1) | IL89352A (de) |
| MX (1) | MX168997B (de) |
| NZ (1) | NZ228105A (de) |
| WO (1) | WO1989007948A1 (de) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6054124A (en) * | 1982-06-03 | 2000-04-25 | Stolle Milk Biologics, Inc. | Immune suppressive product |
| US5194255A (en) * | 1982-06-03 | 1993-03-16 | Stolle Research & Development Corporation | Antihypertensive hyperimmune milk, production, composition, and use |
| US5352462A (en) * | 1982-06-03 | 1994-10-04 | Stolle Research & Development Corporation | Anti-inflammatory factor, method of isolation, and use |
| US4956349A (en) * | 1983-10-27 | 1990-09-11 | Stolle Research & Development Corporation | Anti-inflammatory factor, method of isolation, and use |
| US5863561A (en) * | 1982-06-03 | 1999-01-26 | Stolle Research & Development Corporation | Immune suppressive product |
| US5106618A (en) * | 1987-07-02 | 1992-04-21 | Stolle Research And Development Corporation | Method of treating protozoal gastrointestinal disorders by administering hyperimmune milk product |
| US4994496A (en) * | 1987-09-09 | 1991-02-19 | Repasky Elizabeth A | Use of milk globules as carriers for drugs |
| US5128127A (en) * | 1989-02-08 | 1992-07-07 | Stolle Research & Development Corp. | Increased protein production in animals |
| CA2086101C (en) * | 1990-07-05 | 2002-11-19 | Lee R. Beck | Immune suppressive product from milk |
| CA2136641A1 (en) * | 1992-06-16 | 1993-12-23 | Lee R. Beck | The use of hyperimmune milk to increase longevity |
| US6056978A (en) * | 1992-06-16 | 2000-05-02 | Stolle Milk Biologics, Inc. | Use of hyperimmune milk to prevent suppression of T-lymphocyte production |
| US20040047856A1 (en) * | 2000-11-15 | 2004-03-11 | Williams Charles Edward | Colorstrum-based composition |
| US6770280B1 (en) | 2001-11-15 | 2004-08-03 | Humanetics Corporation | Treatment of menorrhagia, hypermenorrhea, dysmenorrhea and menstrual migraines by the administration of an antibacterial milk product |
| US10716850B2 (en) | 2014-12-31 | 2020-07-21 | Wellin, Inc. | Anti-inflammatory factor retentate, method of isolation, and use |
| US10478493B2 (en) | 2015-08-31 | 2019-11-19 | Stolle Milk Biologics, Inc. | Method of treating protozoal gastrointestinal disorders in immunocompromised patients |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA587849A (en) * | 1959-12-01 | E. Petersen William | Production of protective principle | |
| US2175090A (en) * | 1938-06-22 | 1939-10-03 | Lederie Lab Inc | Purification of antibody compositions |
| US3128230A (en) * | 1961-04-04 | 1964-04-07 | Sunbury Milk Products Co | Milk having antibodies therein and process for producing same |
| US3376198A (en) * | 1965-07-21 | 1968-04-02 | Collins Products Inc | Method of producing antibodies in milk |
| SE337183B (de) * | 1967-04-28 | 1971-07-26 | B Selander | |
| GB1211876A (en) * | 1967-11-23 | 1970-11-11 | Twyford Lab Ltd | Improvements in and relating to prophylactic and therapeutic preparations |
| US3911108A (en) * | 1973-02-14 | 1975-10-07 | Diamond Shamrock Corp | Process of producing bovine milk products containing specific antibodies |
| CH590064A5 (de) * | 1973-11-28 | 1977-07-29 | Biokema Sa | |
| CA1007568A (en) * | 1973-12-13 | 1977-03-29 | Michael C. Attwell | Bovine immunoglobulin isolation process |
| US4324782A (en) * | 1974-01-28 | 1982-04-13 | Beck Lee R | Dental caries inhibiting product of immunized cow's milk having antibodies specific to killed Streptococcus mutans cells |
| US3987161A (en) * | 1974-06-19 | 1976-10-19 | The Procter & Gamble Company | Composition and method for conditioning hair with hair antiserum |
| CH625415A5 (en) * | 1975-05-20 | 1981-09-30 | Stolle Res & Dev | Process for the production of milk with an anticaries action and use thereof for the production of a composition with an anticaries action |
| US4732757A (en) * | 1978-02-06 | 1988-03-22 | Stolle Research And Development Corporation | Prevention and treatment of rheumatoid arthritis |
| FR2452881A1 (fr) * | 1979-04-04 | 1980-10-31 | Bel Fromageries | Procede de preparation de proteines animales ou vegetales, particulierement de lactoproteines, et nouveaux produits ainsi obtenus |
| US4284623A (en) * | 1979-11-09 | 1981-08-18 | Beck Lee R | Method of treating inflammation using bovine milk |
| FR2487642B2 (fr) * | 1980-07-31 | 1985-10-18 | Bel Fromageries | Procede de preparation de fractions proteiques par ultrafiltration et chromatographie d'exclusion et d'echange d'ions |
| ATE16349T1 (de) * | 1981-04-28 | 1985-11-15 | Stolle Res & Dev | Verfahren zur herstellung einer entzuendungshemmenden rindermilch. |
| US4956349A (en) * | 1983-10-27 | 1990-09-11 | Stolle Research & Development Corporation | Anti-inflammatory factor, method of isolation, and use |
| US4636384A (en) * | 1982-06-03 | 1987-01-13 | Stolle Research & Development Corporation | Method for treating disorders of the vascular and pulmonary systems |
| BE901672A (fr) * | 1985-02-07 | 1985-08-07 | Oleofina Sa | Procede de purification de proteines du lait et de ses derives. |
| US4684623A (en) * | 1985-05-02 | 1987-08-04 | The Board Of Trustees Of The Cetus Corporation | Use of tumor necrosis factor as a weight regulator |
| EP0300102B1 (de) * | 1987-07-21 | 1993-03-24 | The Stolle Research And Development Corporation | Verfahren zum Erhalten von immunregulierenden Faktoren mittels Säugetierimmunisierung |
| SE458818B (sv) * | 1987-11-27 | 1989-05-16 | Svenska Mejeriernas Riksforeni | Foerfarande foer utvinning av rena fraktioner av laktoperoxidas och laktoferrin ur mjoelkserum |
-
1988
- 1988-02-26 US US07/161,039 patent/US4879110A/en not_active Expired - Lifetime
-
1989
- 1989-02-16 CA CA000591214A patent/CA1339760C/en not_active Expired - Lifetime
- 1989-02-21 IL IL8935289A patent/IL89352A/en not_active IP Right Cessation
- 1989-02-23 WO PCT/US1989/000718 patent/WO1989007948A1/en not_active Ceased
- 1989-02-23 JP JP1503112A patent/JP2792973B2/ja not_active Expired - Lifetime
- 1989-02-23 AU AU33500/89A patent/AU621604B2/en not_active Ceased
- 1989-02-23 NZ NZ228105A patent/NZ228105A/xx unknown
- 1989-02-24 IE IE60789A patent/IE63032B1/en not_active IP Right Cessation
- 1989-02-24 MX MX015071A patent/MX168997B/es unknown
- 1989-02-27 EP EP89301918A patent/EP0330521B1/de not_active Expired - Lifetime
- 1989-02-27 AT AT89301918T patent/ATE88349T1/de not_active IP Right Cessation
- 1989-02-27 DE DE8989301918T patent/DE68906054T2/de not_active Expired - Lifetime
- 1989-02-27 ES ES198989301918T patent/ES2039847T3/es not_active Expired - Lifetime
-
1990
- 1990-08-22 DK DK201590A patent/DK201590A/da not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP0330521B1 (de) | 1993-04-21 |
| HK1005013A1 (en) | 1998-12-18 |
| MX168997B (es) | 1993-06-16 |
| DE68906054D1 (de) | 1993-05-27 |
| DE68906054T2 (de) | 1993-09-16 |
| DK201590D0 (da) | 1990-08-22 |
| IE63032B1 (en) | 1995-03-22 |
| DK201590A (da) | 1990-08-22 |
| AU621604B2 (en) | 1992-03-19 |
| EP0330521A3 (en) | 1990-10-31 |
| IE890607L (en) | 1989-08-26 |
| US4879110A (en) | 1989-11-07 |
| JPH03505866A (ja) | 1991-12-19 |
| ES2039847T3 (es) | 1993-10-01 |
| AU3350089A (en) | 1989-09-22 |
| WO1989007948A1 (en) | 1989-09-08 |
| NZ228105A (en) | 1990-10-26 |
| IL89352A0 (en) | 1989-09-10 |
| EP0330521A2 (de) | 1989-08-30 |
| JP2792973B2 (ja) | 1998-09-03 |
| ATE88349T1 (de) | 1993-05-15 |
| CA1339760C (en) | 1998-03-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US4879110A (en) | Antihypertensive hyperimmune milk, production, composition, and use | |
| EP0336694B1 (de) | Antientzündungsfaktor aus Milch | |
| CA2090011C (en) | Anti-inflammatory factor, method of isolation, and use | |
| US5352462A (en) | Anti-inflammatory factor, method of isolation, and use | |
| US5194255A (en) | Antihypertensive hyperimmune milk, production, composition, and use | |
| US5980953A (en) | Anti-inflammatory factor, method of isolation, and use | |
| US5650175A (en) | Anti-inflammatory factor, method of isolation, and use | |
| WO1996010410A9 (en) | Anti-inflammatory factor, method of isolation, and use | |
| HK1005013B (en) | Antihypertensive hyperimmune milk | |
| US10716850B2 (en) | Anti-inflammatory factor retentate, method of isolation, and use | |
| HK1007511B (en) | An anti-inflammatory factor from milk |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RH | Patent void |